Tech Company Financing Transactions
Cidara Therapeutics Funding Round
Private investors participated in a $42 million Series B capital raise for Cidara Therapeutics. This venture round was announced on 2/11/2015.
Transaction Overview
Company Name
Announced On
2/11/2015
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will enable us to accelerate the development of our echinocandin antifungal programs, biafungin and topifungin, as well as our immunotherapy platform, Cloudbreak, which, we believe, may represent a fundamentally new approach to the treatment of infectious diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6310 Nancy Ridge Dr. 101
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Cidara is focused on developing novel anti-infectives to address serious infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Stein
Chief Medical Officer
Taylor Sandison
Chief Operating Officer
Paul Daruwala
VP - Bus. Development
Neil Abdollahian
VP - Operations
Laura Navalta
VP - R & D
Les Tari
VP - Regulatory Affairs
Carmen Betancourt
Browse more venture capital transactions:
Prev: 2/11/2015: Soothe venture capital transaction
Next: 2/11/2015: Iris Mobile venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs